Sangamo Therapeutics (SGMO) Financials

Sangamo Therapeutics logo
$0.07 0.00 (0.00%)
As of 11/6/2026
Annual Income Statements for Sangamo Therapeutics

Annual Income Statements for Sangamo Therapeutics

This table shows Sangamo Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-41 -72 -55 -68 -95 -121 -178 -192 -258 -98 -123
Consolidated Net Income / (Loss)
-41 -72 -55 -69 -95 -121 -178 -192 -258 -98 -123
Net Income / (Loss) Continuing Operations
-41 -72 -55 -69 -95 -121 -178 -192 -258 -98 -123
Total Pre-Tax Income
-46 -72 -55 -69 -95 -121 -178 -192 -263 -98 -124
Total Operating Income
-47 -73 -56 -77 -105 -130 -183 -201 -274 -104 -121
Total Gross Profit
40 19 37 84 102 118 111 111 176 58 40
Total Revenue
40 19 37 84 102 118 111 111 176 58 40
Operating Revenue
40 19 37 84 102 118 111 111 176 58 40
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
86 92 93 162 208 248 294 313 450 162 161
Selling, General & Admin Expense
19 26 27 47 62 67 63 63 61 45 35
Research & Development Expense
67 66 66 115 146 181 231 250 234 112 113
Impairment Charge
- - - - - - 0.00 0.00 155 5.52 13
Total Other Income / (Expense), net
0.43 0.89 1.79 8.26 9.76 8.78 5.35 9.43 11 5.86 -2.26
Interest & Investment Income
0.43 0.89 1.79 8.26 9.76 8.78 5.35 9.43 11 1.51 1.30
Other Income / (Expense), net
- - - - - - - - - 4.35 -3.56
Income Tax Expense
-5.72 -0.01 0.00 0.00 0.00 0.35 0.31 0.43 -5.07 -0.17 -0.57
Basic Earnings per Share
($0.58) ($1.02) ($0.70) ($0.70) ($0.85) ($0.90) ($1.23) ($1.25) ($1.48) ($0.49) ($0.44)
Weighted Average Basic Shares Outstanding
69.76M 70.55M 78.08M 96.94M 112.11M 134.45M 144.57M 154.35M 174.44M 201.70M 280.19M
Diluted Earnings per Share
($0.58) ($1.02) ($0.70) ($0.70) ($0.85) ($0.90) ($1.23) ($1.25) ($1.48) ($0.49) ($0.44)
Weighted Average Diluted Shares Outstanding
69.76M 70.55M 78.08M 96.94M 112.11M 134.45M 144.57M 154.35M 174.44M 201.70M 280.19M
Weighted Average Basic & Diluted Shares Outstanding
69.76M 70.55M 78.08M 96.94M 112.11M 134.45M 145.97M 168.48M 178.91M 224.71M 414.27M

Quarterly Income Statements for Sangamo Therapeutics

This table shows Sangamo Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders
-104 -60 -49 -36 9.39 -22 -31 -20 -35 -37 -31
Consolidated Net Income / (Loss)
-104 -60 -49 -36 11 -23 -31 -20 -35 -37 -31
Net Income / (Loss) Continuing Operations
-104 -60 -49 -36 11 -23 -31 -20 -35 -37 -31
Total Pre-Tax Income
-103 -61 -49 -36 11 -24 -30 -20 -35 -38 -31
Total Operating Income
-106 -62 -52 -37 11 -26 -30 -18 -36 -38 -32
Total Gross Profit
9.40 2.04 0.48 0.36 49 8.39 6.44 18 0.58 14 1.44
Total Revenue
9.40 2.04 0.48 0.36 49 8.39 6.44 18 0.58 14 1.44
Operating Revenue
9.40 2.04 0.48 0.36 49 - 6.44 18 0.58 14 1.44
Total Cost of Revenue
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses
116 64 52 37 39 34 36 36 36 52 33
Selling, General & Admin Expense
14 13 12 12 11 9.87 10 9.08 7.99 7.76 6.82
Research & Development Expense
57 51 36 24 28 24 26 27 28 31 27
Total Other Income / (Expense), net
3.52 1.49 2.54 1.03 0.13 2.17 -0.85 -2.10 0.46 0.23 0.95
Interest & Investment Income
3.52 1.49 0.45 0.42 0.35 2.17 0.31 0.39 0.36 0.25 0.30
Other Income / (Expense), net
- - 2.08 0.61 -0.22 - -1.16 -2.49 0.11 -0.02 0.65
Income Tax Expense
1.27 -0.27 0.10 0.07 0.09 -0.43 0.12 0.03 -0.16 -0.55 0.00
Basic Earnings per Share
($0.59) ($0.36) ($0.27) ($0.18) $0.05 ($0.09) ($0.14) ($0.08) ($0.11) ($0.11) ($0.08)
Weighted Average Basic Shares Outstanding
177.17M 174.44M 180.34M 203.95M 208.35M 201.70M 220.27M 256.95M 304.27M 280.19M 389.62M
Diluted Earnings per Share
($0.59) ($0.35) ($0.27) ($0.18) $0.04 ($0.08) ($0.14) ($0.08) ($0.11) ($0.11) ($0.08)
Weighted Average Diluted Shares Outstanding
177.17M 174.44M 180.34M 203.95M 214.33M 201.70M 220.27M 256.95M 304.27M 280.19M 389.62M
Weighted Average Basic & Diluted Shares Outstanding
177.35M 178.91M 207.51M 208.22M 208.65M 224.71M 233.17M 301.71M 336.49M 414.27M 414.29M

Annual Cash Flow Statements for Sangamo Therapeutics

This table details how cash moves in and out of Sangamo Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
63 -47 31 90 -62 51 48 -78 -55 -3.29 -22
Net Cash From Operating Activities
-34 -66 11 37 -144 170 -233 -224 -225 -67 -97
Net Cash From Continuing Operating Activities
-34 -66 11 37 -143 167 -233 -224 -225 -67 -97
Net Income / (Loss) Continuing Operations
-41 -72 -55 -69 -95 -121 -178 -192 -258 -98 -123
Consolidated Net Income / (Loss)
-41 -72 -55 -69 -95 -121 -178 -192 -258 -98 -123
Depreciation Expense
0.99 1.00 1.50 2.36 3.93 5.68 9.44 12 15 5.11 3.96
Amortization Expense
0.83 0.22 -0.67 -5.83 - - 11 7.21 4.80 4.25 3.64
Non-Cash Adjustments To Reconcile Net Income
14 15 9.18 16 19 26 26 32 183 17 22
Changes in Operating Assets and Liabilities, net
-8.43 -11 56 93 -71 256 -102 -82 -170 4.51 -4.22
Net Cash From Investing Activities
77 18 -77 -178 -60 -272 248 59 154 38 -0.10
Net Cash From Continuing Investing Activities
77 18 -77 -178 -60 -272 248 59 154 38 -0.10
Purchase of Property, Plant & Equipment
- -0.73 -3.75 -43 -21 -15 -23 -20 -21 -0.27 -0.10
Sale of Property, Plant & Equipment
- - - - - - - - 0.00 1.95 0.00
Sale and/or Maturity of Investments
338 237 179 392 405 315 610 357 234 36 0.00
Net Cash From Financing Activities
20 0.34 97 232 142 153 33 85 15 28 71
Net Cash From Continuing Financing Activities
20 0.34 97 232 142 153 33 85 15 28 71
Issuance of Common Equity
6.80 1.11 17 16 142 154 36 87 16 29 74
Other Financing Activities, net
13 -0.78 -0.65 0.25 -0.42 -0.77 -3.26 -2.10 -1.45 -0.90 -3.26
Effect of Exchange Rate Changes
- - - - 0.18 -0.45 - 1.25 1.48 -2.05 4.09

Quarterly Cash Flow Statements for Sangamo Therapeutics

This table details how cash moves in and out of Sangamo Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents
-10 -11 8.63 -28 13 2.72 -17 13 -9.32 -9.58 6.64
Net Cash From Operating Activities
-47 -51 -49 -27 12 -3.35 -26 -18 -28 -24 -19
Net Cash From Continuing Operating Activities
-47 -51 -49 -27 12 -3.35 -26 -18 -28 -24 -19
Net Income / (Loss) Continuing Operations
-104 -60 -49 -36 11 -23 -31 -20 -35 -37 -31
Consolidated Net Income / (Loss)
-104 -60 -49 -36 11 -23 -31 -20 -35 -37 -31
Depreciation Expense
5.49 1.83 1.41 1.24 1.22 1.24 1.02 0.99 0.99 0.96 0.72
Amortization Expense
1.76 0.88 0.85 -1.12 3.36 0.89 0.90 0.90 0.91 0.92 0.16
Non-Cash Adjustments To Reconcile Net Income
52 6.40 7.07 6.59 0.96 2.59 2.59 2.27 2.13 15 0.99
Changes in Operating Assets and Liabilities, net
-2.49 0.64 -8.90 2.54 -4.45 15 -0.06 -2.34 2.41 -4.23 9.84
Net Cash From Investing Activities
38 38 36 0.13 0.23 1.32 0.00 -0.02 -0.06 -0.01 -0.01
Net Cash From Continuing Investing Activities
38 38 36 0.13 0.23 1.32 0.00 -0.02 -0.06 -0.01 -0.01
Purchase of Property, Plant & Equipment
-2.74 -2.67 - - -0.12 -0.15 0.00 - -0.06 -0.01 -0.01
Net Cash From Financing Activities
-0.10 0.17 22 -0.53 -0.20 6.99 8.13 29 19 15 27
Net Cash From Continuing Financing Activities
-0.10 0.17 22 -0.53 -0.20 6.99 8.13 29 19 15 27
Issuance of Common Equity
0.00 0.22 23 -0.45 - 7.21 10 29 19 15 27
Other Financing Activities, net
-0.10 -0.05 -0.40 -0.08 -0.20 -0.22 -2.23 -0.42 -0.27 -0.35 -0.38
Effect of Exchange Rate Changes
-0.55 1.35 -0.67 -0.26 1.13 -2.25 1.28 2.73 0.04 0.04 -0.77

Annual Balance Sheets for Sangamo Therapeutics

This table presents Sangamo Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
217 158 287 590 638 939 722 563 165 102 60
Total Current Assets
213 150 248 411 405 660 399 300 94 52 36
Cash & Equivalents
69 22 50 140 80 131 179 100 45 42 21
Accounts Receivable
2.52 4.97 3.34 4.67 37 5.22 6.01 3.68 0.92 0.53 0.37
Prepaid Expenses
0.75 1.85 1.51 5.34 5.41 12 16 18 9.26 5.18 4.37
Current Deferred & Refundable Income Taxes
- - - - - - - - 3.14 4.07 10
Plant, Property, & Equipment, net
2.92 6.56 31 79 30 41 52 64 27 18 11
Total Noncurrent Assets
1.74 1.75 7.28 101 202 238 272 199 44 32 13
Noncurrent Deferred & Refundable Income Taxes
- - - - - - - - 15 13 8.94
Other Noncurrent Operating Assets
0.15 0.17 4.68 6.86 88 86 90 81 29 19 3.94
Total Liabilities & Shareholders' Equity
217 158 287 590 638 939 722 563 165 102 60
Total Liabilities
25 22 99 223 205 441 347 268 82 79 74
Total Current Liabilities
20 13 45 79 70 144 128 112 48 46 42
Accounts Payable
8.23 6.26 11 21 6.67 13 9.76 22 15 15 14
Accrued Expenses
- - - - 11 19 12 16 24 8.20 9.41
Current Deferred Revenue
9.12 4.15 28 48 39 92 86 52 0.00 7.56 0.90
Current Employee Benefit Liabilities
2.75 2.89 5.48 9.49 14 21 21 22 8.92 15 18
Total Noncurrent Liabilities
4.70 8.41 54 145 135 298 219 156 35 33 32
Noncurrent Deferred Revenue
4.70 4.46 29 108 81 245 167 109 0.00 5.87 5.87
Other Noncurrent Operating Liabilities
- 3.95 25 30 47 45 45 40 35 27 26
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
192 136 188 367 433 497 375 295 83 23 -14
Total Preferred & Common Equity
192 136 188 367 433 498 375 295 83 23 -14
Preferred Stock
- - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
192 136 188 367 433 498 375 295 83 23 -14
Common Stock
562 577 684 931 1,092 1,271 1,336 1,452 1,494 1,535 1,614
Retained Earnings
-369 -441 -495 -563 -657 -778 -956 -1,149 -1,406 -1,504 -1,627
Accumulated Other Comprehensive Income / (Loss)
- 0.02 -0.29 -1.44 -2.45 5.42 -3.99 -8.40 -4.60 -7.53 -1.46

Quarterly Balance Sheets for Sangamo Therapeutics

This table presents Sangamo Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets
220 129 93 111 86 98 89 60
Total Current Assets
148 69 40 58 38 50 44 37
Cash & Equivalents
57 54 28 39 25 38 30 28
Accounts Receivable
1.15 0.69 0.58 10 0.37 0.37 0.52 0.87
Prepaid Expenses
14 13 12 8.43 7.81 6.57 8.42 3.16
Current Deferred & Refundable Income Taxes
- - - - 4.24 4.60 4.60 5.49
Plant, Property, & Equipment, net
28 22 21 19 17 16 15 10
Total Noncurrent Assets
44 38 32 34 32 32 30 13
Noncurrent Deferred & Refundable Income Taxes
- 17 14 15 13 14 14 8.76
Other Noncurrent Operating Assets
44 21 19 19 18 17 15 3.78
Total Liabilities & Shareholders' Equity
220 129 93 111 86 98 89 60
Total Liabilities
85 72 69 72 81 78 82 79
Total Current Liabilities
48 40 39 43 50 48 50 53
Accounts Payable
15 15 18 20 18 11 16 19
Accrued Expenses
14 18 16 12 9.80 14 9.87 15
Current Deferred Revenue
1.49 - - 0.77 7.56 7.56 7.56 0.40
Current Employee Benefit Liabilities
17 6.30 5.66 11 14 15 17 18
Total Noncurrent Liabilities
36 32 30 29 32 30 32 26
Noncurrent Deferred Revenue
0.00 - - - 5.87 5.87 5.87 5.87
Other Noncurrent Operating Liabilities
36 32 30 29 26 24 26 20
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
135 57 24 39 4.91 20 6.24 -19
Total Preferred & Common Equity
135 57 24 39 4.91 20 6.24 -19
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
135 57 24 39 4.91 20 6.24 -19
Common Stock
1,488 1,518 1,521 1,524 1,545 1,576 1,598 1,642
Retained Earnings
-1,346 -1,455 -1,492 -1,481 -1,535 -1,555 -1,590 -1,658
Accumulated Other Comprehensive Income / (Loss)
-6.58 -5.80 -5.88 -4.22 -5.53 -1.46 -1.45 -2.51

Annual Metrics And Ratios for Sangamo Therapeutics

This table displays calculated financial ratios and metrics derived from Sangamo Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
70,046,841.00 70,623,858.00 84,520,951.00 102,092,863.00 115,937,618.00 141,441,378.00 145,674,591.00 163,880,007.00 177,346,980.00 - 336,494,489.00
DEI Adjusted Shares Outstanding
70,046,841.00 70,623,858.00 84,520,951.00 102,092,863.00 115,937,618.00 141,441,378.00 145,674,591.00 163,880,007.00 177,346,980.00 - 336,494,489.00
DEI Earnings Per Adjusted Shares Outstanding
-0.58 -1.01 -0.65 -0.67 -0.82 -0.86 -1.22 -1.17 -1.45 - -0.37
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-13.80% -50.96% 88.60% 130.95% 21.29% 15.39% -6.34% 0.54% 58.34% -67.20% -31.57%
EBITDA Growth
-81.84% -58.39% 22.15% -45.17% -25.59% -22.34% -31.47% -11.73% -39.67% 62.67% -29.85%
EBIT Growth
-77.37% -54.86% 22.32% -36.89% -36.33% -23.17% -41.52% -9.79% -36.13% 62.06% -25.28%
NOPAT Growth
-74.96% -54.86% 22.32% -36.89% -36.33% -23.17% -41.52% -9.79% -36.13% 62.06% -16.61%
Net Income Growth
-54.08% -76.05% 23.85% -26.24% -38.51% -26.94% -47.20% -7.84% -34.09% 62.01% -25.52%
EPS Growth
-48.72% -75.86% 31.37% 0.00% -21.43% -5.88% -36.67% -1.63% -18.40% 66.89% 10.20%
Operating Cash Flow Growth
-494.19% -95.38% 116.97% 226.95% -495.08% 217.64% -237.31% 4.13% -0.54% 70.14% -44.79%
Free Cash Flow Firm Growth
-305.07% -68.79% 117.42% -829.72% -99.79% 198.32% -253.31% 6.76% 5.30% 74.91% -32.96%
Invested Capital Growth
16.82% 61.72% -789.91% 41.73% 247.32% -501.77% 54.07% 85.99% 115.06% -1,115.81% -83.91%
Revenue Q/Q Growth
-12.85% -1.02% 12.82% 19.46% 37.65% -19.73% 2.01% -0.67% -12.51% 12.33% 20.31%
EBITDA Q/Q Growth
-33.17% 7.86% -8.74% -11.33% 21.81% -55.88% 8.77% -4.42% -3.45% 27.22% -15.84%
EBIT Q/Q Growth
-31.43% 7.45% -7.51% -9.99% 17.45% -53.04% 1.89% -8.34% -2.49% 25.76% -14.47%
NOPAT Q/Q Growth
-31.43% 7.45% -7.51% -9.99% 17.45% -53.04% 1.89% -8.34% -2.49% 25.76% -11.20%
Net Income Q/Q Growth
-31.26% 5.77% -6.78% -9.76% 19.91% -56.29% 0.91% -8.14% -3.34% 27.37% -12.88%
EPS Q/Q Growth
-31.82% 5.56% -1.45% -2.94% 21.30% 0.00% 0.00% -5.93% -2.07% 35.53% -7.32%
Operating Cash Flow Q/Q Growth
-23.39% -4.21% -31.22% -38.95% 11.81% 10.77% -26.20% -1.98% 2.81% 41.27% -27.64%
Free Cash Flow Firm Q/Q Growth
-17.21% -2.71% -42.33% -110.65% 12.74% 22.71% -21.97% -7.82% 10.76% 45.62% -32.05%
Invested Capital Q/Q Growth
-5.01% 43.65% 15.00% 58.21% 399.98% -12.02% 20.93% 69.55% -32.94% -28,479.10% -45.01%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-113.92% -367.95% -151.87% -95.46% -98.85% -104.80% -147.11% -163.49% -144.21% -164.15% -296.32%
Operating Margin
-118.51% -374.23% -154.13% -91.35% -102.69% -109.61% -165.61% -180.85% -155.48% -179.88% -306.53%
EBIT Margin
-118.51% -374.23% -154.13% -91.35% -102.69% -109.61% -165.61% -180.85% -155.48% -179.88% -315.54%
Profit (Net Income) Margin
-102.94% -369.58% -149.23% -81.57% -93.16% -102.48% -161.06% -172.76% -146.30% -169.45% -310.81%
Tax Burden Percent
87.67% 99.98% 100.00% 100.00% 100.00% 100.29% 100.17% 100.22% 98.07% 99.83% 99.54%
Interest Burden Percent
99.08% 98.78% 96.82% 89.29% 90.72% 93.23% 97.08% 95.31% 95.95% 94.36% 98.96%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% -946.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% -940.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 922.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-20.40% -43.61% -33.67% -24.82% -23.85% -26.04% -40.86% -57.37% -136.47% -185.39% -2,891.84%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% -319.90% 0.00% 0.00% 0.00% -10,939.39% 0.00% 0.00%
Operating Return on Assets (OROA)
-20.35% -38.69% -25.35% -17.59% -17.13% -16.44% -22.08% -31.34% -75.29% -77.89% -154.67%
Return on Assets (ROA)
-17.68% -38.20% -24.55% -15.71% -15.54% -15.37% -21.48% -29.94% -70.85% -73.38% -152.35%
Return on Common Equity (ROCE)
-20.40% -43.61% -33.67% -24.78% -23.83% -26.06% -40.90% -57.37% -136.47% -185.39% -2,891.84%
Return on Equity Simple (ROE_SIMPLE)
-21.15% -52.61% -29.04% -18.80% -22.06% -24.31% -47.50% -65.19% -311.06% -430.13% 0.00%
Net Operating Profit after Tax (NOPAT)
-33 -51 -39 -54 -74 -91 -128 -141 -192 -73 -85
NOPAT Margin
-82.95% -261.96% -107.89% -63.95% -71.88% -76.73% -115.93% -126.59% -108.84% -125.91% -214.57%
Net Nonoperating Expense Percent (NNEP)
-3.63% -11.87% -7.81% -4.62% -5.56% -5.66% -8.64% -13.31% -33.99% -40.94% -121.10%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -231.40% -319.62% 594.81%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
48.55% 135.80% 74.38% 55.34% 60.22% 56.77% 57.11% 56.32% 34.71% 77.38% 88.20%
R&D to Revenue
169.95% 338.43% 179.75% 136.01% 142.46% 152.84% 208.51% 224.53% 132.81% 192.94% 284.87%
Operating Expenses to Revenue
218.51% 474.23% 254.13% 191.35% 202.69% 209.61% 265.61% 280.85% 255.48% 279.88% 406.53%
Earnings before Interest and Taxes (EBIT)
-47 -73 -56 -77 -105 -130 -183 -201 -274 -104 -125
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-45 -71 -56 -81 -101 -124 -163 -182 -254 -95 -117
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.32 1.58 7.38 3.20 2.24 4.43 2.91 1.74 1.16 9.35 0.00
Price to Tangible Book Value (P/TBV)
3.35 1.60 7.44 4.31 2.85 5.56 3.88 2.49 1.16 9.35 0.00
Price to Revenue (P/Rev)
16.17 11.11 37.91 13.88 9.47 18.67 9.87 4.62 0.55 3.68 3.57
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 12.10 0.00 0.00 0.00 8.14 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
10.89 3.76 31.23 9.15 5.72 12.81 5.67 1.86 0.09 2.96 3.04
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 102.14 21.14 0.00 8.91 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 107.44 0.00 0.00 9.94 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.09 -1.07 -1.19 -1.16 -0.98 -1.16 -1.33 -1.15 -1.03 -1.16 -7.39
Leverage Ratio
1.15 1.14 1.37 1.58 1.53 1.69 1.90 1.92 1.93 2.53 18.98
Compound Leverage Factor
1.14 1.13 1.33 1.41 1.39 1.58 1.85 1.83 1.85 2.38 18.78
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.20% 0.04% -0.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 99.80% 99.96% 100.17% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
13.63 1.69 6.33 2.20 1.65 2.17 -0.20 -2.29 -15.27 -21.84 -43.35
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.13% 0.12% -0.07% -0.10% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
10.58 11.25 5.54 5.23 5.80 4.60 3.12 2.69 1.98 1.13 0.84
Quick Ratio
10.54 11.12 5.50 5.16 5.73 4.51 2.99 2.53 1.72 0.93 0.50
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-36 -61 11 -78 -155 152 -234 -218 -206 -52 -69
Operating Cash Flow to CapEx
0.00% -9,000.41% 298.03% 84.87% -698.44% 1,154.51% -1,002.02% -1,108.66% -1,062.83% 0.00% -95,301.96%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.17 0.10 0.16 0.19 0.17 0.15 0.13 0.17 0.48 0.43 0.49
Accounts Receivable Turnover
6.14 5.18 8.80 21.07 4.93 5.61 19.70 22.97 76.61 79.78 88.19
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
17.99 4.09 1.94 1.54 1.89 3.32 2.38 1.93 3.90 2.58 2.73
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
59.49 70.53 41.50 17.32 74.09 65.06 18.53 15.89 4.76 4.58 4.14
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
59.49 70.53 41.50 17.32 74.09 65.06 18.53 15.89 4.76 4.58 4.14
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-17 -6.34 -56 -33 48 -195 -89 -13 1.89 -19 -35
Invested Capital Turnover
-2.17 -1.69 -1.17 -1.89 13.17 -1.62 -0.78 -2.18 -33.15 -6.70 -1.46
Increase / (Decrease) in Invested Capital
3.35 10 -50 24 81 -243 105 77 14 -21 -16
Enterprise Value (EV)
431 73 1,142 773 586 1,514 628 207 15 171 120
Market Capitalization
640 215 1,386 1,172 970 2,207 1,093 515 96 213 141
Book Value per Share
$2.75 $1.93 $2.22 $3.59 $3.73 $3.52 $2.58 $1.80 $0.47 $0.11 ($0.04)
Tangible Book Value per Share
$2.72 $1.91 $2.20 $2.67 $2.93 $2.81 $1.94 $1.26 $0.47 $0.11 ($0.04)
Total Capital
192 136 188 367 433 497 375 295 83 23 -14
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-209 -143 -244 -400 -384 -692 -465 -307 -81 -42 -21
Capital Expenditures (CapEx)
0.00 0.73 3.75 43 21 15 23 20 21 -1.68 0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-17 -6.25 -40 -68 -27 -125 -106 -89 -34 -36 -28
Debt-free Net Working Capital (DFNWC)
192 136 204 332 336 516 271 189 47 5.89 -6.64
Net Working Capital (NWC)
192 136 204 332 336 516 271 189 47 5.89 -6.64
Net Nonoperating Expense (NNE)
7.90 21 15 15 22 30 50 51 66 25 38
Net Nonoperating Obligations (NNO)
-209 -143 -244 -400 -384 -692 -465 -307 -81 -42 -21
Total Depreciation and Amortization (D&A)
1.82 1.22 0.83 -3.47 3.93 5.68 20 19 20 9.09 7.60
Debt-free, Cash-free Net Working Capital to Revenue
-41.77% -32.21% -108.76% -80.66% -26.24% -106.02% -95.45% -79.98% -19.52% -62.34% -69.74%
Debt-free Net Working Capital to Revenue
486.82% 702.92% 556.62% 393.13% 327.65% 436.68% 244.70% 169.47% 26.44% 10.18% -16.78%
Net Working Capital to Revenue
486.82% 702.92% 556.62% 393.13% 327.65% 436.68% 244.70% 169.47% 26.44% 10.18% -16.78%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.58) ($1.02) ($0.70) ($0.70) ($0.85) ($0.90) ($1.23) ($1.25) ($1.48) ($0.49) ($0.44)
Adjusted Weighted Average Basic Shares Outstanding
70.37M 70.88M 86.34M 102.27M 116.02M 143.25M 144.57M 154.35M 174.44M 201.70M 280.19M
Adjusted Diluted Earnings per Share
($0.58) ($1.02) ($0.70) ($0.70) ($0.85) ($0.90) ($1.23) ($1.25) ($1.48) ($0.49) ($0.44)
Adjusted Weighted Average Diluted Shares Outstanding
70.37M 70.88M 86.34M 102.27M 116.02M 143.25M 144.57M 154.35M 174.44M 201.70M 280.19M
Adjusted Basic & Diluted Earnings per Share
($0.58) ($1.02) ($0.70) ($0.70) ($0.85) ($0.90) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
69.76M 70.55M 78.08M 96.94M 112.11M 134.45M 145.97M 168.48M 178.91M 224.71M 414.27M
Normalized Net Operating Profit after Tax (NOPAT)
-33 -51 -39 -54 -74 -91 -128 -141 -83 -69 -76
Normalized NOPAT Margin
-82.95% -261.96% -107.89% -63.95% -71.88% -76.73% -115.93% -126.59% -47.26% -119.23% -191.15%
Pre Tax Income Margin
-117.42% -369.65% -149.23% -81.57% -93.16% -102.19% -160.79% -172.37% -149.18% -169.74% -312.25%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Sangamo Therapeutics

This table displays calculated financial ratios and metrics derived from Sangamo Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding
177,111,718.00 177,346,980.00 178,906,350.00 207,510,076.00 208,220,670.00 - 224,710,019.00 233,166,972.00 301,709,485.00 336,494,489.00 414,274,017.00
DEI Adjusted Shares Outstanding
177,111,718.00 177,346,980.00 178,906,350.00 207,510,076.00 208,220,670.00 - 224,710,019.00 233,166,972.00 301,709,485.00 336,494,489.00 414,274,017.00
DEI Earnings Per Adjusted Shares Outstanding
-0.59 -0.34 -0.27 -0.17 0.05 - -0.14 -0.09 -0.12 -0.11 -0.07
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-64.48% -92.50% -99.70% -94.79% 425.77% 310.77% 1,238.25% 5,042.13% -98.82% 88.43% -77.60%
EBITDA Growth
-97.35% -16.67% -309.11% 69.25% 115.12% 59.80% 38.84% 49.25% -323.83% -67.39% -5.39%
EBIT Growth
-93.84% -12.04% -374.16% 70.49% 109.78% 58.12% 37.73% 44.21% -440.50% -58.48% -1.65%
NOPAT Growth
-93.84% -12.04% -301.84% 69.99% 114.16% 58.12% 42.50% 51.85% -336.03% -46.99% -7.82%
Net Income Growth
-95.96% -16.01% -332.29% 68.45% 110.25% 61.20% 37.67% 44.68% -427.31% -59.94% -1.30%
EPS Growth
-73.53% -9.38% -325.00% 72.73% 106.78% 77.14% 48.15% 55.56% -375.00% -37.50% 42.86%
Operating Cash Flow Growth
11.80% 11.41% 26.60% 55.72% 124.86% 93.37% 46.27% 32.46% -342.35% -628.23% 26.26%
Free Cash Flow Firm Growth
-7.31% 49.97% 140.12% 116.16% 111.34% 104.91% -98.43% -92.76% -104.99% -475.85% 334.64%
Invested Capital Growth
106.84% 115.06% -98.56% -107.95% -102.38% -1,115.81% -1,586.36% -357.57% -36,146.27% -83.91% -129.56%
Revenue Q/Q Growth
37.50% -78.27% -76.44% -25.99% 13,779.78% -83.02% -14.75% 184.39% -96.83% 2,348.88% -89.87%
EBITDA Q/Q Growth
16.12% 40.15% 20.49% 22.97% 141.23% -286.98% -32.94% 36.08% -81.85% -8.33% 16.30%
EBIT Q/Q Growth
13.89% 41.68% 20.33% 26.24% 128.54% -344.47% -27.65% 33.92% -74.22% -7.84% 18.13%
NOPAT Q/Q Growth
13.89% 41.68% 16.97% 28.03% 140.62% -272.54% -14.00% 39.74% -99.12% -7.45% 16.38%
Net Income Q/Q Growth
9.03% 42.11% 18.59% 26.40% 129.54% -319.23% -30.78% 34.68% -74.77% -7.13% 17.17%
EPS Q/Q Growth
10.61% 40.68% 22.86% 33.33% 122.22% -300.00% -75.00% 42.86% -37.50% 0.00% 27.27%
Operating Cash Flow Q/Q Growth
22.10% -6.86% 3.71% 44.75% 143.74% -128.50% -680.33% 30.56% -56.94% 14.37% 20.99%
Free Cash Flow Firm Q/Q Growth
35.44% 51.15% 198.85% -48.16% -54.72% -78.84% -68.37% 139.04% -131.16% -1,495.29% 136.58%
Invested Capital Q/Q Growth
-94.54% -32.94% -27.64% -400.29% 98.36% -28,479.10% -5.88% 7.56% -29.58% -45.01% -32.16%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-1,055.05% -2,906.37% -9,810.60% -10,210.11% 30.33% -284.39% -448.39% -100.78% -5,774.18% -255.42% -2,109.43%
Operating Margin
-1,132.24% -3,039.13% -10,712.27% -10,416.85% 21.52% -309.85% -460.28% -97.54% -6,119.28% -268.51% -2,215.40%
EBIT Margin
-1,132.24% -3,039.13% -10,279.00% -10,244.38% 21.07% -309.85% -478.28% -111.14% -6,100.86% -268.65% -2,170.25%
Profit (Net Income) Margin
-1,108.35% -2,952.74% -10,205.61% -10,148.31% 21.60% -278.92% -475.33% -109.18% -6,012.05% -263.00% -2,149.45%
Tax Burden Percent
101.23% 99.55% 100.20% 100.21% 99.18% 98.21% 100.39% 100.14% 99.54% 98.54% 100.00%
Interest Burden Percent
96.70% 97.60% 99.09% 98.86% 103.36% 91.66% 99.00% 98.10% 99.00% 99.34% 99.04%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% -2,930.77% -3,776.64% 813.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% -2,921.99% -3,766.95% 813.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 2,207.13% 3,072.97% -800.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-112.37% -136.47% -723.65% -703.67% 12.97% -185.39% -257.94% -292.47% -480.02% -2,891.84% 1,755.71%
Cash Return on Invested Capital (CROIC)
-8,219.91% -10,939.39% -306.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-560.60% -1,471.75% -677.03% -601.65% 6.66% -134.17% -283.49% -95.30% -2,006.60% -131.69% -1,026.44%
Return on Assets (ROA)
-548.78% -1,429.92% -672.19% -596.00% 6.82% -120.78% -281.74% -93.62% -1,977.39% -128.91% -1,016.60%
Return on Common Equity (ROCE)
-112.37% -136.47% -723.65% -703.67% 12.97% -185.39% -257.94% -292.47% -480.02% -2,891.84% 1,755.71%
Return on Equity Simple (ROE_SIMPLE)
-184.93% 0.00% -578.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-74 -43 -36 -26 11 -18 -21 -12 -25 -27 -22
NOPAT Margin
-792.57% -2,127.39% -7,498.59% -7,291.80% 21.34% -216.89% -322.19% -68.28% -4,283.49% -187.95% -1,550.78%
Net Nonoperating Expense Percent (NNEP)
-12.30% -8.68% -8.79% -9.69% 0.15% -8.47% -24.49% -22.64% -28.81% -33.97% -32.72%
Return On Investment Capital (ROIC_SIMPLE)
- -52.41% -63.62% -109.58% 26.94% -79.90% -422.74% -63.76% -398.64% 187.43% 117.98%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
148.10% 641.48% 2,446.36% 3,383.43% 22.36% 117.62% 156.27% 49.58% 1,375.56% 54.53% 472.82%
R&D to Revenue
607.46% 2,483.15% 7,461.75% 6,804.21% 56.12% 282.25% 404.01% 147.95% 4,843.72% 220.96% 1,842.58%
Operating Expenses to Revenue
1,232.24% 3,139.13% 10,812.27% 10,516.85% 78.49% 399.87% 560.28% 197.54% 6,219.28% 368.51% 2,315.40%
Earnings before Interest and Taxes (EBIT)
-106 -62 -49 -36 10 -26 -31 -20 -35 -38 -31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-99 -59 -47 -36 15 -24 -29 -18 -34 -36 -30
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.79 1.16 2.11 3.14 4.61 9.35 30.04 6.44 32.54 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.79 1.16 2.11 3.14 4.61 9.35 30.04 6.44 32.54 0.00 0.00
Price to Revenue (P/Rev)
0.53 0.55 6.39 6.06 3.45 3.68 2.31 1.54 6.18 3.57 2.96
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 8.14 47.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.09 3.44 3.79 2.70 2.96 1.92 1.08 5.25 3.04 2.16
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.09 -1.03 -0.76 -0.82 -0.98 -1.16 -1.31 -1.53 -1.54 -7.39 3.76
Leverage Ratio
1.83 1.93 1.45 1.62 1.90 2.53 3.49 4.40 4.41 18.98 -10.40
Compound Leverage Factor
1.77 1.88 1.44 1.61 1.97 2.32 3.46 4.32 4.36 18.86 -10.30
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-7.97 -11.04 -15.66 -22.96 -16.19 -19.31 -24.46 -21.17 -24.66 -38.57 -39.40
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.04 1.98 1.71 1.03 1.35 1.13 0.76 1.05 0.88 0.84 0.70
Quick Ratio
2.76 1.72 1.37 0.73 1.15 0.93 0.52 0.81 0.60 0.50 0.54
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-118 -58 57 30 13 2.84 0.90 2.15 -0.67 -11 3.90
Operating Cash Flow to CapEx
-1,723.51% -1,892.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -44,528.13% -174,307.14% -148,323.08%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.50 0.48 0.07 0.06 0.32 0.43 0.59 0.86 0.33 0.49 0.47
Accounts Receivable Turnover
71.05 76.61 4.86 7.45 8.98 79.78 120.64 171.47 5.97 88.19 55.78
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
4.77 3.90 0.46 0.30 2.20 2.58 3.28 4.50 1.94 2.73 2.54
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
5.14 4.76 75.09 49.01 40.64 4.58 3.03 2.13 61.17 4.14 6.54
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
5.14 4.76 75.09 49.01 40.64 4.58 3.03 2.13 61.17 4.14 6.54
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
2.81 1.89 1.36 -4.10 -0.07 -19 -20 -19 -24 -35 -47
Invested Capital Turnover
-10.52 -33.15 0.39 0.52 38.11 -6.70 -6.74 -7.16 -2.70 -1.46 -1.03
Increase / (Decrease) in Invested Capital
44 14 -93 -56 -2.88 -21 -22 -15 -24 -16 -26
Enterprise Value (EV)
-26 15 65 47 141 171 122 88 173 120 75
Market Capitalization
106 96 120 74 180 213 147 126 203 141 102
Book Value per Share
$0.76 $0.47 $0.32 $0.11 $0.19 $0.11 $0.02 $0.08 $0.02 ($0.04) ($0.05)
Tangible Book Value per Share
$0.76 $0.47 $0.32 $0.11 $0.19 $0.11 $0.02 $0.08 $0.02 ($0.04) ($0.05)
Total Capital
135 83 57 24 39 23 4.91 20 6.24 -14 -19
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-132 -81 -55 -28 -39 -42 -25 -38 -31 -21 -28
Capital Expenditures (CapEx)
2.74 2.67 0.00 0.00 -0.23 -1.32 0.00 0.00 0.06 0.01 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-33 -34 -27 -27 -24 -36 -37 -36 -37 -28 -44
Debt-free Net Working Capital (DFNWC)
99 47 28 1.07 15 5.89 -12 2.23 -6.05 -6.64 -16
Net Working Capital (NWC)
99 47 28 1.07 15 5.89 -12 2.23 -6.05 -6.64 -16
Net Nonoperating Expense (NNE)
30 17 13 10 -0.13 5.20 9.86 7.49 10 11 8.63
Net Nonoperating Obligations (NNO)
-132 -81 -55 -28 -39 -42 -25 -38 -31 -21 -28
Total Depreciation and Amortization (D&A)
7.25 2.71 2.25 0.12 4.58 2.14 1.92 1.90 1.90 1.88 0.88
Debt-free, Cash-free Net Working Capital to Revenue
-16.39% -19.52% -143.63% -217.61% -46.34% -62.34% -58.26% -44.20% -111.26% -69.74% -126.19%
Debt-free Net Working Capital to Revenue
49.20% 26.44% 151.39% 8.72% 28.63% 10.18% -18.77% 2.73% -18.40% -16.78% -46.36%
Net Working Capital to Revenue
49.20% 26.44% 151.39% 8.72% 28.63% 10.18% -18.77% 2.73% -18.40% -16.78% -46.36%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.59) ($0.36) ($0.27) ($0.18) $0.05 ($0.09) ($0.14) ($0.08) ($0.11) ($0.11) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding
177.17M 174.44M 180.34M 203.95M 208.35M 201.70M 220.27M 256.95M 304.27M 280.19M 389.62M
Adjusted Diluted Earnings per Share
($0.59) ($0.35) ($0.27) ($0.18) $0.04 ($0.08) ($0.14) ($0.08) ($0.11) ($0.11) ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding
177.17M 174.44M 180.34M 203.95M 214.33M 201.70M 220.27M 256.95M 304.27M 280.19M 389.62M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
177.35M 178.91M 207.51M 208.22M 208.65M 224.71M 233.17M 301.71M 336.49M 414.27M 414.29M
Normalized Net Operating Profit after Tax (NOPAT)
-43 -43 -33 -25 11 -18 -21 -12 -25 -17 -22
Normalized NOPAT Margin
-458.89% -2,117.24% -6,865.68% -7,061.35% 21.34% -216.89% -322.19% -68.28% -4,283.49% -122.84% -1,550.78%
Pre Tax Income Margin
-1,094.84% -2,966.06% -10,185.24% -10,127.53% 21.78% -284.01% -473.48% -109.03% -6,039.76% -266.88% -2,149.45%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Sangamo Therapeutics remains in a difficult financial position despite some improvement in the latest quarter. Q1 2026 revenue fell to $1.4 million, down from $14.2 million in Q4 2025 and $6.4 million in Q1 2025. The company reported a $31.0 million net loss, although this was an improvement from the $37.4 million loss in Q4 2025.

Operating expenses also declined to $33.4 million in Q1 2026 from $52.4 million in Q4, when Sangamo recorded a $13.2 million impairment charge. Research and development spending remained substantial at $26.6 million, representing the majority of operating expenses. Sangamo has not yet demonstrated sustained profitability or positive operating cash flow.

Cash flow trends remain concerning. The company used $19.3 million in operating cash during Q1 2026, following operating cash outflows of $24.4 million in Q4 2025, $28.5 million in Q3 2025 and $18.2 million in Q2 2025. Q1’s $6.6 million increase in cash was primarily supported by a $27.1 million common-equity issuance, rather than operations.

Sangamo ended Q1 2026 with $27.6 million in cash and equivalents. At the latest quarterly operating cash-burn rate, that balance alone would provide roughly one to two quarters of funding, although actual runway will depend on additional financing, spending changes and potential partnership or licensing proceeds.

The balance sheet has weakened significantly. Total liabilities of $78.9 million exceeded total assets of $60.0 million, leaving the company with negative equity of $19.0 million. Current liabilities were $53.1 million compared with $37.1 million of current assets, indicating limited short-term liquidity. The company’s reliance on repeated equity offerings has also materially increased dilution: weighted-average basic shares rose from 180.3 million in Q1 2024 to 389.6 million in Q1 2026.

  • Operating expenses declined to $33.4 million in Q1 2026, helped by lower research and development and selling, general and administrative spending compared with Q4 2025.
  • The Q1 2026 net loss narrowed to $31.0 million from $37.4 million in Q4 2025, and the quarter did not include the large impairment charge recorded in the prior quarter.
  • Capital expenditures remained minimal at just $13,000 in Q1 2026, limiting near-term investment-related cash demands.
  • Interest and investment income, along with other income, contributed $951,000 in Q1 2026, but these amounts are too small to offset the company’s operating losses.
  • Revenue declined sharply to $1.4 million in Q1 2026 from $14.2 million in Q4 2025, highlighting the volatility and lack of a dependable revenue base.
  • Operating cash flow remained negative at $19.3 million in Q1 2026, continuing a multiquarter pattern of substantial cash consumption.
  • The company generated a $6.6 million quarterly cash increase primarily through issuing $27.1 million of common equity, increasing reliance on external financing.
  • Cash and equivalents fell from $54.4 million in Q1 2024 to $27.6 million in Q1 2026, even after multiple equity raises.
  • Total liabilities exceeded total assets by $19.0 million at March 31, 2026, while current liabilities exceeded current assets, signaling significant balance-sheet stress.
  • Weighted-average basic shares outstanding more than doubled from 180.3 million in Q1 2024 to 389.6 million in Q1 2026, creating substantial dilution risk for existing shareholders.
11/22/26 08:50 AM ETAI Generated. May Contain Errors.

Sangamo Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sangamo Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Sangamo Therapeutics' net income appears to be on a downward trend, with a most recent value of -$122.93 million in 2025, falling from -$40.70 million in 2015. The previous period was -$97.94 million in 2024. See Sangamo Therapeutics' forecast for analyst expectations on what's next for the company.

Sangamo Therapeutics' total operating income in 2025 was -$121.24 million, based on the following breakdown:
  • Total Gross Profit: $39.55 million
  • Total Operating Expenses: $160.79 million

Over the last 10 years, Sangamo Therapeutics' total revenue changed from $39.54 million in 2015 to $39.55 million in 2025, a change of 0.0%.

In the past 10 quarters, Sangamo Therapeutics' cash and equivalents has ranged from $25.18 million in Q1 2025 to $56.51 million in Q3 2023, and is currently $27.59 million as of their latest financial filing in Q1 2026.

Sangamo Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Sangamo Therapeutics' book value per share changed from 2.75 in 2015 to -0.04 in 2025.



Financial statements for NASDAQ:SGMO last updated on 7/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners